The stock's fall snapped a three-day winning streak.

Arish Global Services, the all-in-one solution for web lead generation based in the UK, announced today its partnership with ...

A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

This was the stock's third consecutive day of gains.

Vertex Global Services partners with UK-based Arish Global Services to create over 5,000 jobs in India, boosting the ...

Like its competitors, Google continues to experiment with low- and no-code tools that harness agentic AI for business ...

Fintel reports that on January 3, 2025, Raymond James downgraded their outlook for Vertex (NasdaqGM:VERX) from Outperform to ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

Vertex (VERX – Research Report) received a Hold rating and price target from Raymond James analyst Alexander Sklar today. The company’s ...